Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 18/20 | 0.67 |
| ▸ | FGFR4 | P22455 | 17/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.67 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18003765 | 0.91 | FGFR4 (0.68) | FGFR1FGFR4FGFR2FGFR3KIT | |
| SCHEMBL18004374 | 0.87 | FGFR4 (0.64) | FGFR1FGFR4FGFR2FGFR3KIT | |
| SCHEMBL18004379 | 0.87 | FGFR4 (0.64) | FGFR1FGFR4FGFR2FGFR3KIT | |
| SCHEMBL18000666 | 0.85 | FGFR4 (0.71) | FGFR1FGFR4FGFR2FGFR3KIT | |
| SCHEMBL18004295 | 0.83 | FGFR1 (0.68) | FGFR1FGFR4FGFR2FGFR3KIT | |
| SCHEMBL21318788 | 0.82 | FGFR1 (0.76) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL6250154 | 0.81 | FGFR4 (0.66) | FGFR1FGFR4FGFR2FGFR3KIT | |
| SCHEMBL18011756 | 0.81 | FGFR1 (0.83) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL30500630 | 0.81 | FGFR4 (0.70) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL18004212 | 0.81 | FGFR4 (0.70) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024547-B | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| CN-113024547-A | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特公司 | 2021-06-25 | — | — | CN | disclosed |
| US-11014923-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014923-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| CN-107438608-B | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20190241560-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2018-08-30 | — | — | US | disclosed |
| US-9890156-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890156-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890156-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3259270-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | Incyte Corporation (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016134314-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
| US-11014923-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
| US-20190241560-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 1/4885FGFR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.